Thrombosis and Haemostasis

Antithrombotic prophylaxis with rivaroxaban in patients with prehospital COVID-19: A meta-analysis of two placebo-controlled trials

Judith Hsia, Alex C Spyropoulos, Gregory Piazza, Stephen Weng, Michael Dunne, Concetta Lipardi, Elliot Barnathan, Marc Bonaca.

Affiliations below.

DOI: 10.1055/a-2216-5848


Conflict of Interest: Drs. Hsia and Bonaca receive salary support from CPC, a non-profit academic research organization affiliated with the University of Colorado, that receives research grant/consulting funding from: Agios Pharmaceuticals, Inc., Alexion Pharma Gado Kaisha, Amgen Inc., Anthos Therapeutics, Inc., ARCA biopharma, Inc., AstraZeneca Pharma India, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Ltd, AstraZeneca®Produtos Farmaceúticos, Lda, Atentiv, LLC, Bayer, Bayer (Proprietary) Limited, Bayer Aktiengesellschaft, Bayer Pharma AG, Beth Israel Deaconess Medical Center, Better Therapeutics, Blonest Partners Inc., Boston Clinical Research Institute, LLC, Bristol-Myers Squibb, CellResearch Corporation Pte Ltd, Cleerly, Inc., Colorado Dept of Public Health and Environment, Cook Regentec LLC, CSL Behring LLC, Eidos Therapeutics, Inc., EPG Communication Holdings Ltd., Esperion Therapeutics, Inc, Faraday Pharmaceuticals, Inc., HeartFlow Inc, Hummingbird Bioscience PTE. LTD., Inamed, Ionis Pharmaceuticals, IQVIA Inc., Janssen Pharmaceuticals, Inc, Janssen Research & Development, LLC, Janssen Scientific Affairs LLC, Lexicon Pharmaceuticals, Inc., LSG Corporation, MedImmune Limited, Medpace, Inc., Medscape, Merck Sharp & Dohme Corp., Northwell Health, Novartis Pharmaceuticals Corporation, Novo Nordisk, Osiris Therapeutics, Inc., Pfizer, PPD Development, L.P., Prothena Biosciences Limited, Regeneron, Regents of the University of Colorado, Sanofi, Sanofi-Aventis, Sanofi, Silence Therapeutics PLC, Stanford University, Stealth BioTherapeutics Inc., The Brigham & Women’s Hospital, Inc., Thrombosis Research Institute, UCD ic42 Lab, University of Colorado Denver, University of Pittsburgh, VarmX, WraSer, LLC. Dr. Hsia also reports owning AstraZeneca stock. Dr. Spyropoulos has received research support from Boehringer Ingelheim, Janssen and AstraZeneca and consulting fees from Janssen, Bristol-Meyers Squibb/Pfizer Alliance, Sanofi, Alexion, Boehringer Ingelheim, Bayer, Roche Diagnostics, AstraZeneca. Dr. Piazza has received research support from Bristol-Myers Squibb/Pfizer Alliance, Bayer, Janssen, Alexion, Amgen and Boston Scientific Corporation, and consulting fees from Bristol-Myers Squibb/Pfizer Alliance, Boston Scientific Corporation, Janssen, NAMS, Prairie Education and Research Cooperative, Boston Clinical Research Institute, and Amgen. Dr. Dunne reports no potential conflicts of interest. Drs. Weng, Lipardi, and Barnathan were employees of Janssen Research and Development during the conduct of PREVENT-HD. Dr. Bonaca receives support from the AHA SFRN under award numbers 18SFRN3390085 (BWH-DH SFRN Center) and 18SFRN33960262 (BWH-DH Clinical Project) and also reports stock in Medtronic and Pfizer.

This study was supported by Janssen Pharmaceuticals (http://dx.doi.org/10.13039/100008897)

Trial registration: NCT04508023, ClinicalTrials.gov (http://www.clinicaltrials.gov/), randomized, placebo controlled, multicenter

Abstract:

Background
We conducted a prespecified meta-analysis of two randomized, placebo-controlled trials of rivaroxaban 10 mg daily in prehospital patients with acute COVID-19. Individually, the trials had limited power to detect a treatment effect due to recruitment stopping ahead of plan.

Methods
The statistical analysis plan for the meta-analysis was finalized before unblinding of PREVENT-HD, the larger of the two trials.
Pooled risk ratios and pooled risk differences along with the 2-sided 95% confidence intervals were calculated using random-effect models.

Findings
Rivaroxaban did not reduce the occurrence of either the primary prespecified endpoint, a composite of symptomatic arterial and venous thromboembolism, myocardial infarction, ischemic stroke, acute limb ischemia, all-cause hospitalization and all-cause mortality (risk difference 0.0044, 95% confidence interval -0.0263, 0.0175; p=0.69 for pooled risk difference) or the secondary endpoint of all-cause hospitalization (p=0.76). Although thrombotic events were infrequent, pooled analysis did reveal that rivaroxaban reduced arterial and venous thrombotic events (placebo 6 events, rivaroxaban 0 events; pooled risk difference -0.0068, 95% confidence interval -0.0132, -0.0006; p=0.03). In the pooled studies, only one major bleeding event was observed in a rivaroxaban-allocated patient with no critical site or fatal bleeding events.

Interpretation
Although this meta-analysis does not support antithrombotic prophylaxis with rivaroxaban in a broad prehospital population with acute COVID-19, the prevention of arterial and venous thrombotic events among rivaroxaban-allocated patients is consistent with the known thromboprophylactic effect of the drug in medically ill patients.

Corresponding Author:
Dr. Judith Hsia, CPC Clinical Research, 2115 N Scranton St #2040, 80045 Aurora, United States, judith.hsia@cpcmed.org

Affiliations:
Judith Hsia, CPC Clinical Research, Aurora, United States
Alex C Spyropoulos, Hofstra, Northwell School of Medicine, Department of Medicine, Northwell Health at Lenox Hill Hospital, NY, United States
Gregory Piazza, Brigham and Women’s Hospital Department of Medicine, Boston, United States
Marc Bonaca, CPC Clinical Research, Aurora, United States
Supplementary material

Supplementary Figure. Forest plot of pooled risk ratios for the primary composite endpoint (p=0.73, upper panel) and all-cause hospitalization (p=0.77, lower panel). Note that pooled risk ratios for thrombotic events and ISTH major bleeds are not provided as no events were observed for some categories.

Articles reporting antithrombotic trials in patients with prehospital COVID-19 identified through database search

The meta-analysis reported in this paper was prespecified in the PREVENT-HD statistical analysis plan. To consider our analysis in the context of other antithrombotic trials, we searched PubMed and EBSCO for individual randomized, controlled trials of antithrombotic therapy in patients with prehospital COVID-19 and identified 39 articles. After eliminating duplicates, trials not enrolling patients with prehospital COVID-19, not studying antithrombotic interventions or...
articles not reporting randomized trials with clinical endpoints, 4 articles remained. Of these, 2 evaluated enoxaparin (Cools 2022, Barco 2022), 1 colchicine and aspirin, each vs usual care in a factorial design, and 1 compared apixaban, aspirin and placebo (Connors 2021). Clinical event rates were low and no significant impact of antithrombotic therapy was observed.

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barco 2022</td>
<td>Enoxaparin vs standard of care</td>
<td>Untoward hospitalization/death HR 0·98 (95% CI 0·37–2·56); p=0·96</td>
</tr>
<tr>
<td>N=472</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cools 2022</td>
<td>Enoxaparin vs standard of care</td>
<td>All-cause hospitalization/death HR 1·09 (95% CI 0·49–2·43); p=0·83</td>
</tr>
<tr>
<td>N=219</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eikelboom 2022</td>
<td>Aspirin 100 mg qd vs usual care</td>
<td>Major thrombosis/hospitalization/death HR 0·80 (95% CI 0·57–1·13); p=0·21</td>
</tr>
<tr>
<td>N=3881</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Connors 2021</td>
<td>Aspirin vs placebo</td>
<td>Death/symptomatic thromboembolism/myocardial infarction/stroke/hospitalization for CV or pulmonary cause</td>
</tr>
<tr>
<td>N=657</td>
<td>Apixaban 2.5 mg bid vs placebo</td>
<td>Risk difference in percentage points vs placebo 0.0% (95% CI not calculable)</td>
</tr>
<tr>
<td></td>
<td>Apixaban 5 mg bid vs placebo</td>
<td>Risk difference in percentage points vs placebo 0.7% (95% CI –2.1% to 4.1%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Risk difference in percentage points vs placebo 1.4% (95% CI –1.5% to 5.0%)</td>
</tr>
</tbody>
</table>

Antithrombotic prophylaxis with rivaroxaban in patients with prehospital COVID-19: A meta-analysis of two placebo-controlled trials

Judith Hsia, Alex C. Spyropoulos, Gregory Piazza, Stephen Weng, Michael W. Dunne, Concetta Lipardi, Elliot S. Barnathan, Marc P. Bonaca

1Colorado Prevention Center and Department of Medicine, University of Colorado, Aurora, CO, USA, 2Feinstein Institutes for Medical Research and Department of Medicine, Northwell Health, New York, NY, USA, 3Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA, 4Janssen Research and Development, Statistical Decision Sciences, Cardiovascular and Metabolism, High Wycombe, UK, 5Bill and Melinda Gates Medical Research Institute, Cambridge, MA, USA, 6Janssen Research and Development, Clinical Development, Raritan, NJ, USA

Corresponding author: Dr. Judith Hsia, judith.hsia@cpcmed.org. CPC Clinical Research, 2115 N Scranton Street #2040, Aurora, CO 80045-7120

Abstract

Background We conducted a prespecified meta-analysis of two randomized, placebo-controlled trials of rivaroxaban 10 mg daily in prehospital patients with acute COVID-19. Individually, the trials had limited power to detect a treatment effect due to recruitment stopping ahead of plan.
Methods

The statistical analysis plan for the meta-analysis was finalized before unblinding of PREVENT-HD, the larger of the two trials. Pooled risk ratios and pooled risk differences along with the 2-sided 95% confidence intervals were calculated using random-effect models.

Findings

Rivaroxaban did not reduce the occurrence of either the primary prespecified endpoint, a composite of symptomatic arterial and venous thromboembolism, myocardial infarction, ischemic stroke, acute limb ischemia, all-cause hospitalization and all-cause mortality (risk difference 0.0044, 95% confidence interval -0.0263, 0.0175; p=0.69 for pooled risk difference) or the secondary endpoint of all-cause hospitalization (p=0.76). Although thrombotic events were infrequent, pooled analysis did reveal that rivaroxaban reduced arterial and venous thrombotic events (placebo 6 events, rivaroxaban 0 events; pooled risk difference -0.0068, 95% confidence interval -0.0132, -0.0006; p=0.03). In the pooled studies, only one major bleeding event was observed in a rivaroxaban-allocated patient with no critical site or fatal bleeding events.

Interpretation

Although this meta-analysis does not support antithrombotic prophylaxis with rivaroxaban in a broad prehospital population with acute COVID-19, the prevention of arterial and venous thrombotic events among rivaroxaban-allocated patients is consistent with the known thromboprophylactic effect of the drug in medically ill patients.

Keywords: COVID-19, clinical trial: direct thrombin agent, meta-analysis
What is known on this topic?

- Several randomized trials have been conducted to assess the role of antithrombotic prophylaxis to reduce morbidity and mortality among patients not requiring hospitalization at the time of COVID-19 diagnosis.
- All were stopped ahead of plan due to recruitment challenges, lower than expected clinical event rates or futility, leading to inconclusive results.

What does this paper add?

- This meta-analysis of the 2 placebo-controlled trials of rivaroxaban was prespecified.
- By augmenting the number of clinical endpoint events in the 2 trials of similar design and using the same antithrombotic intervention, this analysis increased power to address the clinically important question of whether prehospital patients benefit from prophylactic anticoagulation.

Introduction

Among patients with acute coronavirus disease 2019 (COVID-19), the vast majority have not required hospitalization.1,2 Several randomized trials have been conducted to assess the role of antithrombotic prophylaxis to reduce the risk of hospitalization, death and thrombotic events such as venous thromboembolism (VTE), myocardial infarction (MI), and ischemic stroke in those who did not require hospitalization at the time of COVID-19 diagnosis, termed “prehospital” patients.3-10 All the trials were stopped ahead of plan due to recruitment challenges, lower than expected clinical event rates or futility, leading to inconclusive results.
Three of these randomized trials evaluated rivaroxaban 10 mg daily in patients with prehospital COVID-19.\textsuperscript{7-9} Two trials were placebo-controlled, focused on extended thromboprophylaxis of 21 days or longer and enrolled non-hospitalized, ambulatory patients with COVID-19 in the United States.\textsuperscript{8,9} Leveraging an increased number of events by merging the two studies of similar design and utilizing the same antithrombotic intervention to potentially improve power, we conducted a prespecified meta-analysis to address the clinically important question of whether prehospital patients benefit from this prophylactic anticoagulant regimen.

Methods

The designs of the GATES MRI (NCT04504032) and PREVENT-HD (NCT04508023) have been previously reported (Figure 1).\textsuperscript{8,11} GATES MRI was conducted from August 2020 to February 2021; PREVENT-HD from August 2020 to April 2022. The planned sample sizes for GATES MRI and PREVENT-HD were 600 and 4000 patients, respectively. Both studies had independent data monitoring committees. GATES MRI was stopped when the futility boundary was crossed at a planned interim analysis. PREVENT-HD was stopped early due to enrollment challenges and a lower-than-expected blinded pooled event rate.

Study population: For both studies, eligible patients were required to have acute symptomatic COVID-19 infection, at least 1 high-risk characteristic and an initial treatment plan that did not include hospitalization. For GATES MRI high risk characteristics included age >65 years, self-reported obesity and chronic conditions requiring daily treatment. For PREVENT-HD high risk characteristics included age >60 years, body mass index >35kg/m\textsuperscript{2}, elevated D-dimer, history of VTE or thrombophilia or other chronic conditions (coronary, peripheral artery or cerebrovascular disease, cancer, diabetes or heart failure). Those requiring routine anticoagulation for high-risk
clotting conditions or at high bleeding risk were excluded from both studies. The population for the meta-analysis included PREVENT-HD and GATES MRI specifically to focus on a US COVID-19 population and extended thromboprophylaxis of at least 21 days.

Intervention: Eligible participants were randomized (1:1) to rivaroxaban 10 mg daily or placebo equivalent (multivitamin) for 21 days in GATES MRI or to rivaroxaban 10 mg daily or identical-appearing placebo for 35 days in PREVENT-HD. The rivaroxaban dose was selected to balance prevention of venous and arterial thrombosis with bleeding risk based on prior data in medically ill patients. For both studies, study medication was delivered to the patient’s home via a centralized pharmacy service.

Study procedures: Both studies enrolled patients in the United States and were entirely remotely conducted. GATES MRI recruited at 13 outpatient clinics in 7 states and 1 virtual site which enrolled patients from 40 states. PREVENT-HD recruited through 14 integrated health care delivery networks. Healthcare encounters, thrombotic, bleeding and other adverse events were collected during remote follow-up contacts (telehealth or virtual visit). Follow-up duration was 35 days for GATES MRI and 49 days for PREVENT-HD.

Clinical endpoints: The primary endpoint prespecified in the meta-analysis statistical analysis plan was the PREVENT-HD primary endpoint, a composite of symptomatic VTE, MI, ischemic stroke, acute limb ischemia, non-central nervous system systemic embolism, all-cause hospitalization, and all-cause mortality. For the GATES MRI study, the primary efficacy endpoint was progression to moderate or severe disease (GATES MRI scale 3 or higher). Those with GATES MRI scale 3 had at least 1 of the following: shortness of breath, tachypnea (respiratory rate ≥20 breathes/minute) or hypoxemia. Scales 4 to 7 progressed from critically ill status to death. The secondary endpoint for the meta-analysis was all-cause hospitalization,
which was a secondary endpoint for each of the individual studies. Occurrence of thrombotic events was evaluated as a component of the primary composite endpoint in PREVENT-HD and as an adverse event in GATES MRI. Safety was assessed using the International Society on Thrombosis and Haemostasis (ISTH) bleeding classification. Clinical events in PREVENT-HD were classified by a blinded, centrally trained clinical endpoint committee with at least one member in each health system, enabling review of the full electronic medical record. In the GATES MRI study, clinical events were classified by site investigators using standardized definitions.

**Statistical methods:** The statistical analysis plan for the meta-analysis was finalized before PREVENT-HD was unblinded and prespecified the inclusion of data from the PREVENT-HD and GATES MRI trials. Data were extracted from published summary data outputs from both studies for reported follow-up durations. The primary efficacy endpoint was defined in the PREVENT-HD as the occurrence of all major venous and arterial thrombotic events (symptomatic VTE, MI, ischemic stroke, acute limb ischemia, and non-CNS systemic embolization), all-cause hospitalization, and all-cause mortality. The most similar primary efficacy endpoint was extracted from the Gates MRI summary tables, by using the reported hospitalization data combined with reported adverse events related to venous and arterial thrombotic events. The secondary efficacy endpoint as defined in the PREVENT-HD was the occurrence of all-cause hospitalization. The results of the secondary endpoint of all-cause hospitalization, were extracted from summary data from the Gates MRI trial data to directly map to the all-cause hospitalization endpoint of the PREVENT-HD study. Finally, an exploratory endpoint was defined as occurrence of all major venous and arterial thrombotic events, extracted
from the summary efficacy tables from PREVENT-HD study and summary adverse events tables from the Gates MRI study.

Under the random-effects model, the true effect sizes are allowed to differ, due to possible differences in the participant characteristics, follow-up duration, time period or general design differences between studies (heterogeneity). The meta-analysis was implemented using aggregate summary data with a random-effects model to account for between-study heterogeneity using inverse variance weighting. The pooled point estimates and 2-sided 95% confidence intervals are therefore presented, with $I^2$ as a measure of the degree of between study heterogeneity. We calculated the risk ratio (RR) and 95% confidence interval (CI) for incidence of composite outcomes. Pooled risk differences (RD) and corresponding 95% CI were calculated for component outcomes if there were zero events in either trial arm. Analyses were conducted on the intention-to-treat population defined as all randomized subjects.

**Results**

In aggregate, GATES MRI and PREVENT-HD randomly allocated 1728 patients with acute COVID-19 to rivaroxaban 10 mg daily or placebo. Baseline characteristics are summarized (Table 1). PREVENT-HD recruited an older cohort with more non-white participants (Black, Asian, American Indian or Alaskan native). The trials enrolled a similar proportion of Hispanic or Latino participants, who could be white or non-white. Both cohorts enrolled patients with elevated body mass index, a similar proportion with diabetes mellitus and more women than men.

For the primary composite endpoint of symptomatic VTE, MI, ischemic stroke, acute limb ischemia, non-central nervous system systemic embolism, all-cause hospitalization, and all-cause mortality, rivaroxaban had an overall neutral effect in pooled RD analysis (RD 0.0044,
95% CI -0.0263, 0.0175; p=0.69; Figure 2, panel A). Similarly, rivaroxaban was not observed to reduce all-cause hospitalization compared with placebo (RD -0.0036, 95% CI -0.0271, 0.0198; p=0.76; Figure 2, panel B). Pooled RR for the composite and all-cause hospitalization endpoints are shown in the Supplementary Materials. No significant heterogeneity was observed for any of these analyses.

Arterial and venous thrombotic events were infrequent overall and observed less frequently with rivaroxaban compared with placebo (pooled RD -0.0068, 95% CI -0.0132, -0.0006; p=0.03). In the GATES MRI study, one patient in the placebo group had VTE and in PREVENT-HD, three patients in the placebo group had at least one VTE and two patients had an ischemic stroke. In aggregate, no arterial or venous thrombotic events were identified among rivaroxaban-allocated patients (Figure 2, panel C).

Major bleeding was rare with only one major bleed identified in a rivaroxaban-allocated patient in PREVENT-HD and none in the GATES MRI study (p=0.53 vs placebo, Figure 3). No critical site or fatal bleeding events were observed. Based on the pooled RD between treatment groups, rivaroxaban would be estimated to result in 13 major bleeding events per 10,000 patients treated. Assessing the potential benefit against the potential risk in these two trials, prehospital rivaroxaban treatment of 10,000 patients with acute COVID-19 could prevent 69 arterial and venous thrombotic events while resulting in 13 major bleeds (Visual summary).

Discussion

In the individual trials, both of which were terminated prior to completing planned enrollment, and the meta-analysis, rivaroxaban 10 mg daily was not observed to reduce a composite endpoint of thrombotic events, all-cause hospitalization and death among prehospital patients with
COVID-19, nor all-cause hospitalization. Consistent with its mechanism of action and established efficacy and safety in thromboprophylaxis for medically ill patients, rivaroxaban reduced arterial or venous thrombotic events with a very low risk of major bleeding.

In addition to clinical outcomes data, the trials also provide useful lessons for clinical trial conduct during future pandemics. Both PREVENT-HD and GATES MRI demonstrated the feasibility of conducting entirely remote randomized, controlled trials including delivery of study medication to participants’ homes in a population with acute, symptomatic infectious disease. Despite the absence of in-person contact or established relationships with investigators or site personnel, nearly all participants completed study participation. PREVENT-HD was conducted in large health systems which may have facilitated retention (0/1284 lost to follow up) whereas GATES MRI was conducted at outpatient clinics and a virtual site which enrolled patients in 40 states (15/497 [3%] lost to follow up). No problems were encountered with identification and management of adverse events in either study.

During the early stages and certainly during subsequent surges, the vast majority of patients with COVID-19 did not require hospitalization. In August 2020, when both GATES MRI and PREVENT-HD were initiated, approximately 330,000 cases/week were identified in the US of which 41,000 were hospitalized (12%). As such, we, along with other investigators, evaluated therapies intended to reduce the need for hospitalization at a time when health resource needs exceeded capacity. Rapid initiation of PREVENT-HD and GATES MRI was possible due to accelerated procedures for COVID-19 trials implemented by health authorities and healthcare institutions, and the established dosing and safety profile for rivaroxaban in medically ill outpatients. The proportion of patients with COVID-19 requiring hospitalization fell to approximately 8% by February 2021 when GATES MRI completed, and to 5% by April 2022.
when PREVENT-HD completed. Overall, the magnitude of the problem under study diminished as both the proportion of patients with COVID-19 requiring hospitalization and the incidence of thrombotic events fell.

Although our pre-specified meta-analysis included the PREVENT-HD and Gates MRI trials with rivaroxaban, 3 other studies in prehospital patients studied different factor Xa inhibitors or treatment duration.\textsuperscript{5-7} All were stopped ahead of plan due to lower than expected clinical event rates and/or waning of the pandemic; antithrombotic therapy did not significantly reduce clinical events in any of the trials.

The randomized antithrombotic trials in patients with prehospital COVID-19 focused on detecting a reduction in hospitalization, reflecting the belief that thrombosis was a key driver of disease progression leading to hospitalization.\textsuperscript{15} As our understanding of the pathophysiology has evolved in parallel with the dynamic landscape of viral variants, vaccines and anti-viral medications, it has become apparent that micro- and macro-thrombosis are just two of the mechanisms contributing to the clinical syndrome and deterioration and hospitalization. Unlike established effects on reducing macrovascular thrombosis, whether anticoagulants reduce thrombotic microangiopathy and thromboinflammatory mechanisms that can lead to worsening disease severity in COVID-19 and other infectious disorders is still a matter of debate.\textsuperscript{16}

This meta-analysis does demonstrate that rivaroxaban reduced thrombotic events in prehospital COVID-19, consistent with its established antithrombotic effect in other populations, including the medically ill.\textsuperscript{12,17} The frequency of thrombotic events among patients with prehospital COVID-19 was considerably lower than that of hospitalized patients.\textsuperscript{18} In the prehospital COVID-19 trials of antithrombotic therapies,\textsuperscript{3,9} thrombotic events were identified in
only 0.9% of control group-allocated patients, an incidence which would not support thromboprophylaxis with either a direct oral anticoagulant or low-molecular weight heparin.

Strengths of this meta-analysis are the similarities in the two trials’ study designs and use of the same anticoagulant regimen. Pooled analysis mitigated, at least in part, the shortfall in statistical power due to early closure; in this meta-analysis, the previously observed lack of effect of rivaroxaban on the composite endpoint and all-cause hospitalization is corroborated. Although the analysis of thrombotic events is consistent with rivaroxaban’s known mechanism of action and antithrombotic effect in diverse patient populations, the limited number of events and post-hoc nature of the analysis are limitations. Another potential limitation is the difference between the primary endpoint prespecified in the meta-analysis statistical analysis plan and the Gates MRI primary endpoint of disease progression. This is unlikely to have affected completeness of clinical event ascertainment since all-cause hospitalization was the secondary endpoint in Gates MRI and there were no deaths. Results of this meta-analysis are in-line with the National Institutes of Health antithrombotic guideline for COVID-19 updated October 10, 2023, which recommends against routine pre-hospital thromboprophylaxis. Although thrombosis was quite infrequent, rivaroxaban did reduce the frequency of arterial and venous thrombotic events with a low rate of major bleeding. Based on recent estimates of disease emergence from zoonotic reservoirs associated with climate change, the probability of extreme epidemics has been projected to increase up to 3-fold in the near term. Having established the safety and antithrombotic efficacy of this rivaroxaban regimen may prove useful when a population at particularly high thrombotic risk is identified in a future pandemic.

19

20
Acknowledgements

The Gates MRI study was supported by grants from Gates Philanthropy Partnerships and the Bill and Melinda Gates Foundation. PREVENT-HD was funded by Janssen Pharmaceuticals.

Conflict of interest disclosure

VarmX, WraSer, LLC. Dr. Hsia also reports owning AstraZeneca stock. Dr. Spyropoulos has received research support from Boehringer Ingelheim, Janssen and AstraZeneca and consulting fees from Janssen, Bristol-Meyer Squibb/Pfizer Alliance, Sanofi, Alexion, Boehringer Ingelheim, Bayer, Roche Diagnostics, AstraZeneca. Dr. Piazza has received research support from Bristol-Myers Squibb/Pfizer Alliance, Bayer, Janssen, Alexion, Amgen and Boston Scientific Corporation, and consulting fees from Bristol-Myers Squibb/Pfizer Alliance, Boston Scientific Corporation, Janssen, NAMSA, Prairie Education and Research Cooperative, Boston Clinical Research Institute, and Amgen. Dr. Dunne reports no potential conflicts of interest. Drs. Weng, Lipardi, and Barnathan were employees of Janssen Research and Development during the conduct of PREVENT-HD. Dr. Bonaca receives support from the AHA SFRN under award numbers 18SFRN3390085 (BWH-DH SFRN Center) and 18SFRN33960262 (BWH-DH Clinical Project) and also reports stock in Medtronic and Pfizer.

References


Table 1. Baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>GATES MRI</th>
<th>PREVENT-HD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rivaroxaban</td>
<td>Control</td>
</tr>
<tr>
<td>n</td>
<td>222</td>
<td>222</td>
</tr>
<tr>
<td>Age, years</td>
<td>49</td>
<td>49</td>
</tr>
<tr>
<td>Female, %</td>
<td>57</td>
<td>64</td>
</tr>
<tr>
<td>Non-white, %</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>Hispanic/Latino, %</td>
<td>22</td>
<td>18</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>35</td>
<td>33</td>
</tr>
<tr>
<td>Diabetes mellitus, %</td>
<td>26</td>
<td>30</td>
</tr>
</tbody>
</table>

Figure 1. Study designs
Figure 2. Forest plots of the effect of rivaroxaban on clinical efficacy endpoints

A. Composite endpoint

<table>
<thead>
<tr>
<th></th>
<th>Rivaroxaban</th>
<th>Placebo</th>
<th>Risk Difference</th>
<th>IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events</td>
<td>22</td>
<td>641</td>
<td>Total</td>
<td>643</td>
</tr>
<tr>
<td>Total Weight</td>
<td>3</td>
<td>222</td>
<td>Total Weight</td>
<td>222</td>
</tr>
<tr>
<td>Risk Difference</td>
<td>0.0049</td>
<td>0.0240</td>
<td>Risk Difference</td>
<td>0.0049</td>
</tr>
<tr>
<td>p</td>
<td>0.04</td>
<td>0.005</td>
<td>p</td>
<td>0.04</td>
</tr>
</tbody>
</table>

Events per 10,000 patients: -44 (95% CI -263 to 175)

B. All-cause hospitalization

<table>
<thead>
<tr>
<th></th>
<th>Rivaroxaban</th>
<th>Placebo</th>
<th>Risk Difference</th>
<th>IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events</td>
<td>21</td>
<td>222</td>
<td>Total</td>
<td>222</td>
</tr>
<tr>
<td>Total Weight</td>
<td>7</td>
<td>222</td>
<td>Total Weight</td>
<td>222</td>
</tr>
<tr>
<td>Risk Difference</td>
<td>0.0036</td>
<td>0.0018</td>
<td>Risk Difference</td>
<td>0.0036</td>
</tr>
<tr>
<td>p</td>
<td>0.04</td>
<td>0.005</td>
<td>p</td>
<td>0.04</td>
</tr>
</tbody>
</table>

Events per 10,000 patients: -36 (95% CI -271 to 198)

C. Thrombotic events

<table>
<thead>
<tr>
<th></th>
<th>Rivaroxaban</th>
<th>Placebo</th>
<th>Risk Difference</th>
<th>IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events</td>
<td>0</td>
<td>222</td>
<td>Total</td>
<td>222</td>
</tr>
<tr>
<td>Total Weight</td>
<td>5</td>
<td>222</td>
<td>Total Weight</td>
<td>222</td>
</tr>
<tr>
<td>Risk Difference</td>
<td>0.0045</td>
<td>0.0079</td>
<td>Risk Difference</td>
<td>0.0045</td>
</tr>
<tr>
<td>p</td>
<td>0.03</td>
<td>0.005</td>
<td>p</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Events per 10,000 patients: -69 (95% CI -133 to -5)
Figure 3. Forest plot of the effect of rivaroxaban on ISTH major bleeding

<table>
<thead>
<tr>
<th>Study</th>
<th>Rivaroxaban</th>
<th>Placebo</th>
<th>Total</th>
<th>Total</th>
<th>Total</th>
<th>Weight</th>
<th>Risk Difference</th>
<th>IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>PREVENT-HD</td>
<td>1</td>
<td>599</td>
<td>6</td>
<td>598</td>
<td>78.0%</td>
<td>0.0017</td>
<td>[0.00029; 0.0063]</td>
<td></td>
</tr>
<tr>
<td>GATES MRI</td>
<td>0</td>
<td>219</td>
<td>20</td>
<td>230</td>
<td>22.0%</td>
<td>0.0000</td>
<td>[0.00087; 0.0087]</td>
<td></td>
</tr>
</tbody>
</table>

Total (95% CI) = 818 828 100.0% 0.0013 [0.0028; 0.0054]

Events per 10,000 patients: **13 (95% CI -28 to 54)**

p=0.53

Figure 1. Study designs and meta-analysis plan
COVID-19, coronavirus disease 2019; VTE, venous thromboembolism; MI, myocardial infarction; CNS, central nervous system; ISTH, International Society on Thrombosis and Haemostasis; AE, adverse event

Figure 2. Forest plots of the effect of rivaroxaban on clinical efficacy endpoints

Figure 3. Forest plot of the effect of rivaroxaban on ISTH bleeding
Pooled risk difference for ISTH major bleeding
ISTH, International Society on Thrombosis and Haemostasis
Arterial and Thrombotic Events

49 (95% CI: 18.3–5.9)
p = 0.031

Major Bleeding

13 (95% CI: 2.9–5.6)
p = 0.53